TransMedics Group (NASDAQ:TMDX – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14, Briefing.com reports. TransMedics Group had a net margin of 0.84% and a return on equity of 17.37%. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. During the same quarter last year, the firm posted ($0.03) EPS. TransMedics Group’s revenue was up 117.7% compared to the same quarter last year. TransMedics Group updated its FY 2024 guidance to EPS.
TransMedics Group Trading Up 6.5 %
Shares of TMDX opened at $151.51 on Friday. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $171.98. The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18. The stock has a market cap of $4.99 billion, a PE ratio of -445.62 and a beta of 1.99. The business’s 50-day moving average price is $143.82 and its 200-day moving average price is $110.58.
Insider Transactions at TransMedics Group
In other news, CEO Waleed H. Hassanein sold 30,000 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $130.07, for a total transaction of $3,902,100.00. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,017,905.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Waleed H. Hassanein sold 30,000 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $130.07, for a total transaction of $3,902,100.00. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,017,905.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Nicholas Corcoran sold 3,222 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $129.91, for a total value of $418,570.02. Following the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $2,741,750.55. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 101,342 shares of company stock valued at $13,642,015. 7.00% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
View Our Latest Research Report on TMDX
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Stories
- Five stocks we like better than TransMedics Group
- What is a Secondary Public Offering? What Investors Need to Know
- Generac Raises Guidance: Why Is the Stock Still a Hold?
- How to Use the MarketBeat Stock Screener
- Iconic Burger Chain’s Stock Rallies, Defying Market Trends
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- First Solar Stock: The Dawn of a New Rally in Share Prices
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.